Asa Ren leverages advanced artificial intelligence (AI) and real-world evidence (RWE) to enhance personalized healthcare solutions. The company focuses on utilizing clinico-genomic data to improve patient outcomes and facilitate early disease prevention. With over 2 million RWE data points and 679,000 unique datasets, Asa Ren is committed to driving innovation across various healthcare segments, including individuals, healthcare providers, and life sciences. Their AI-assisted platform provides a two-way user interface that allows both healthcare providers and patients to access comprehensive health data, enabling personalized treatment recommendations and real-time health scores.

The company also emphasizes collaboration within the healthcare ecosystem, offering valuable insights to pharmaceutical and health stakeholders for drug discovery, clinical trials, and biomarker validation. Asa Ren's approach includes collecting multi-modal RWE to support research breakthroughs and deliver impactful solutions. By creating a unified health ecosystem, Asa Ren aims to enhance patient care, support decision-making, and generate new revenue opportunities through data collaboration, ultimately empowering individuals to take charge of their health and well-being.

Indonesia

Established in 2016, Asa Rén is the 1st DNA data company in Indonesia with the most comprehensive bioinformatics in South East Asia. We aim to enable innovation in Indonesia's healthcare industry through utilization of longitudinal data and genomic data for drug discovery and personalized treatments. 

Asa Ren

Company Details